What, if any, role does systemic therapy have in the treatment of HCC amenable to definitive locoregional therapy?

For ablation, TACE and Y90, I traditionally hold back on systemic therapy so that I have something I can use if they develop metastases. Also, sorafenib has been not shown to be effective in the adjuvant setting so I apply that principle here. Bruix et al., PMID 26361969